The drug stocks have been able to continue their uptrend during the first half of 2011 and are easily beating the overall market. The PHLX Drug Sector Index is up 8% year-to-date as the S&P 500 is only up 3.8%.
For years, the major drug makers have been viewed as "has-beens" due to their lack of new drug discoveries and less-than-promising futures. But recently, three strong factors are driving investors to the sector. The combination of attractive values, above-average dividend yields and the perception of a "safety" sector all rolled together have attracted money.

TUTORIAL: The Industry Handbook: Biotechnology

Top Picks
My top picks in the sector (in no specific order) begin with Novartis (NYSE:NVS), the Swiss pharmaceutical firm. The company offers products that include innovative drugs, eye care products, generic drugs, consumer health products, vaccines and animal health products. Its top two selling drugs are Diovan and Gleevec, a hypertension and cancer drug, respectively. Fundamentally the stock trades with a forward P/E ratio of 10.5 and pays a dividend of 3.3%. After hitting a fresh all-time high earlier this month, the stock has pulled back to support and is now a very attractive opportunity.

Pfizer (NYSE:PFE) is another global pharmaceutical company based in the U.S. that offers products across 11 therapeutic areas. Some of the company's well-known drugs include Viagra, Celebrex and Chantix. The stock trades with a forward P/E ratio of 9.0 and pays a 4.0% dividend. Technically the stock is well off its all-time high. But it is consolidating near a yearly high, and a breakout above $22 would be a bullish signal.

Allergan (NYSE:AGN) is not as diverse as the first two companies and is divided into two divisions - specialty pharmaceuticals and medical devices. I always think of the company as the "stay young" drug company. Two of its biggest products are Botox and breast implants. With the baby boomers sitting on cash and getting older, it only makes sense they will run to AGN for their products. Fundamentally, the company trades with a forward P/E ratio of 19.8 and pays a small dividend of 0.2%. The stock is currently sitting less than 1 percent from a new all-time high, and it appears it is poised to break the record in the very near future.

Drug ETF
Investors that do not want to concentrate on an individual stock have the option of an ETF. One of my favorites is the PowerShares Pharmaceuticals ETF (NYSE:PJP). The ETF consists of 30 stocks and charges an annual expense ratio of 0.63%. The top holding, Abbott Labs (NYSE:ABT), makes up 5% of the portfolio, and both AGN and PFE are listed in the top 20 holdings. The distribution yield is a low 0.9%.

The Bottom Line
To me, there are two major risks in investing in the major pharmaceutical stocks. First, if the market rallies, the big money could rotate out of healthcare stocks and into higher beta stocks. The second risk is that approval of new drugs becomes tougher, thus lowering the sector's growth. That being said, all sectors have specific risks that investors must weigh. (For related reading, see Pharmaceutical Sector: Does The FDA Help Or Harm?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  4. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  5. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  6. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  7. Chart Advisor

    How Are You Trading The Breakdown In Growth Stocks? (VOOG, IWF)

    Based on the charts of these two ETFs, bearish traders will start turning their attention to growth stocks.
  8. Mutual Funds & ETFs

    Pimco’s Top Funds for Retirement Income

    Once you're living off the money you've saved for retirement, is it invested in the right assets? Here are some from PIMCO that may be good options.
  9. Chart Advisor

    Watch This ETF For Signs Of A Reversal (BCX)

    Trying to determine if the commodity markets are ready for a bounce? Take a look at the analysis of this ETF to find out if now is the time to buy.
  10. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>
Trading Center